Mirabilis Therapeutics

Mirabilis Therapeutics is a biopharmaceutical company specializing in the development of microRNA-based therapies for cardiovascular diseases. The company's core technology focuses on identifying and modulating specific microRNAs that drive disease progression in the heart. Its lead program, MRB-001, is an antisense oligonucleotide targeting miR-199a-3p, which has been shown to play a critical role in cardiac hypertrophy and heart failure. Mirabilis was founded as a spin-off from Maastricht University, building on the pioneering research of Professor Leon de Windt. The company has previously entered into strategic collaborations, including an option agreement with Servier, to advance its therapeutic pipeline toward clinical validation.